Form 4: Biogen Director Susan Langer Acquires 2,370 Shares

Biogen Inc. Director Susan Langer has acquired 2,370 shares of common stock at a price of $0, increasing her direct beneficial ownership to 5,129.1 shares.

Summary

• Susan Langer, a Director at Biogen Inc. (BIIB), acquired 2,370 shares of common stock.
• The transaction occurred on June 17, 2025, and the shares were acquired at a price of $0 per share, indicating a likely stock grant or award.
• Following this acquisition, Ms. Langer's direct beneficial ownership of Biogen common stock stands at 5,129.1 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine disclosure of a stock grant to a director, which is an expected part of compensation and does not inherently signal significant positive or negative operational or financial news for the company.

Positives

• The acquisition of shares by a director, even at a $0 price (likely a grant), aligns the director's interests with those of shareholders, demonstrating continued commitment to the company's performance.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in the biotechnology and pharmaceutical industry where executive and director compensation often includes equity grants to align interests with long-term company performance.

Related Party Transactions

• The acquisition of shares by Susan Langer, a Director of Biogen Inc., constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The grant of shares to a director aligns management's interests with shareholder value creation, potentially fostering long-term growth.
• Employees: While not directly impacting general employees, such compensation practices are part of the overall corporate governance and compensation structure.

Key Dates

Keywords

Biogen, BIIB, Susan Langer, Director, Insider Trading, SEC Form 4, Share Acquisition, Stock Grant, Beneficial Ownership